Department of Oncology, Hanoi Medical University, Hanoi, Vietnam.
Department of On-demand Breast,Gynecologic, Head and Neck Medical Oncology, Hanoi Oncology Hospital, Hanoi, Vietnam.
Clin Ter. 2024 Nov-Dec;175(6):412-421. doi: 10.7417/CT.2024.5148.
Identifying predictors of pathological complete response (pCR) and long-term outcomes after neoadjuvant treatment for breast cancer is needed to individualize treatment and patient monitoring. This study aimed to investigate clinicopathological factors affecting pCR and long-term outcomes in stage III breast cancer patients receiving a dose-dense neoadjuvant regimen.
This is a retrospective study including patients with stage III breast cancer who received neoadjuvant chemotherapy consisting of doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m², followed by paclitaxel 175 mg/m² every two weeks at Vietnam National Cancer Hospital and Hanoi Oncology Hospital between January 2015 and December 2022. Logistic and Cox regression were used to investigate the association between clinicopathological factors and pCR and long-term outcomes, respectively.
A total of 211 patients were included in the study. Univariate analysis found an association of pCR with clinical tumor (cT) stage, grade, hormone receptor status, HER2, Ki67, and St. Gallen classification. Multivariate analysis identified several predictors of pCR: cT stage (cT3/T4 vs cT1/T2: OR: 0.3; p = 0.01); grade (grade 3 vs grade 1-2: OR: 1.6; p = 0.035); and hormone receptor status (nega-tive vs. positive: OR: 2.9; p = 0.011). Two independent prognostic factors for event-free survival (EFS) were identified: hormone receptor status (negative vs. positive: HR: 2.1; p = 0.044) and pCR (No pCR vs. pCR: HR: 3.0; p = 0.018). Hormone receptor status was also the only independent prognostic factor for overall survival (OS) (negative vs. positive: HR: 2.6; p=0.039).
Low cT stage, grade 3, and hormone receptor-negative status were independent predictors of pCR. Hormone receptor-positive status and pCR were independent prognostic factors for better EFS, while hormone receptor-positive status was the only independent prognostic factor for better OS.
为了实现治疗和患者监测的个体化,需要确定新辅助治疗后乳腺癌病理完全缓解(pCR)和长期结局的预测因素。本研究旨在调查接受密集型新辅助方案治疗的 III 期乳腺癌患者的临床病理因素对 pCR 和长期结局的影响。
这是一项回顾性研究,纳入了 2015 年 1 月至 2022 年 12 月在越南国家癌症医院和河内肿瘤医院接受多柔比星 60mg/m²联合环磷酰胺 600mg/m²新辅助化疗,随后每两周接受紫杉醇 175mg/m²治疗的 III 期乳腺癌患者。采用逻辑回归和 Cox 回归分析分别研究临床病理因素与 pCR 和长期结局之间的关系。
共纳入 211 例患者。单因素分析发现 pCR 与临床肿瘤(cT)分期、分级、激素受体状态、HER2、Ki67 和圣加仑分类有关。多因素分析确定了 pCR 的几个预测因素:cT 分期(cT3/T4 与 cT1/T2:OR:0.3;p = 0.01);分级(3 级与 1-2 级:OR:1.6;p = 0.035);和激素受体状态(阴性与阳性:OR:2.9;p = 0.011)。事件无进展生存(EFS)的两个独立预后因素是:激素受体状态(阴性与阳性:HR:2.1;p = 0.044)和 pCR(无 pCR 与 pCR:HR:3.0;p = 0.018)。激素受体状态也是总生存(OS)的唯一独立预后因素(阴性与阳性:HR:2.6;p=0.039)。
低 cT 分期、3 级和激素受体阴性状态是 pCR 的独立预测因素。激素受体阳性状态和 pCR 是 EFS 更好的独立预后因素,而激素受体阳性状态是 OS 更好的唯一独立预后因素。